Analyzing Relmada Therapeutics (NASDAQ:RLMD) & Minerva Neurosciences (NASDAQ:NERV)

Relmada Therapeutics (NASDAQ:RLMD) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Valuation & Earnings

This table compares Relmada Therapeutics and Minerva Neurosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38 million	($1.45)	-4.82
Minerva Neurosciences	N/A	N/A	-$293.42 million	($26.80)	-0.20

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Relmada Therapeutics has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Relmada Therapeutics and Minerva Neurosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1	1	4	1	2.71
Minerva Neurosciences	1	1	0	0	1.50

Relmada Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 71.67%. Minerva Neurosciences has a consensus price target of $7.00, suggesting a potential upside of 32.58%. Given Relmada Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Relmada Therapeutics is more favorable than Minerva Neurosciences.

Profitability

This table compares Relmada Therapeutics and Minerva Neurosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-170.83%	-145.58%
Minerva Neurosciences	N/A	N/A	-35.62%

Institutional and Insider Ownership

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 20.7% of Relmada Therapeutics shares are owned by insiders. Comparatively, 10.4% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Relmada Therapeutics beats Minerva Neurosciences on 9 of the 12 factors compared between the two stocks.

About Relmada Therapeutics

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

About Minerva Neurosciences

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.